# Cedilla Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cedilla-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.cedillatx.com
- Total disclosed funding: $111M
- Latest round: Series B (Oct 25, 2021)
- Investors on record: 9

## About

Founded in 2018 and based in Massachusetts, US, Cedilla Therapeutics, Inc. operates as a biotechnology company that develops small-molecule therapeutics that target cancer drivers and treat life-threatening diseases. It focuses on destabilizing oncoprotein targets that include direct ligand-induced degradation, upstream regulators, protein orphaning, and proteome susceptibility mapping.

## Funding rounds

- Series B, Oct 25, 2021, $25M — Third Rock Ventures, RA Capital Management, Janus Henderson Investors, Woodline Partners, Logos Capital
- Series B, Sep 24, 2020, $30M — Schroders Capital, Third Rock Ventures, Casdin Capital, Eli Lilly & Company, Boxer Capital
- Series A, Apr 24, 2018, $56M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Eli Lilly & Company — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Janus Henderson Investors — Series B
- Woodline Partners — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B